Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

Le-Qing Cao; Wen-Xuan Huo; Er-Lie Jiang; Yue-Wen Fu; Xiao-Jun Xu; Ping-Chong Lei; Ming-Feng Zhao; Zhi Chen; Shu-Xia Guo; Xiao-Bing Huang; Yan-Ming Zhang; Xian-Jing Wang; Guan-Chen Bai; Feng-Bo Jin; Qing-Sheng Li; Ming-Yang Deng; Hao Zhang; Xin-Feng Wang; Xiao-Jun Huang; Xiao-Dong Mo

doi:10.1186/s40779-025-00640-0

Your Location：

Home >

Browse articles >

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

RESEARCH | Updated：2025-10-14

- Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study
- “Xenopax, a humanized interleukin-2 receptor antagonist, has shown promising results in treating steroid-refractory acute graft-versus-host disease, with a 64.5% overall response rate within 28 days and 82.6% at any time after treatment. This multicenter study provides valuable insights into the efficacy and safety of xenopax in real-world settings.”
- Military Medical Research Vol. 12, (2025)
- Affiliations：
  
  1.Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China
  2.State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
  3.Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
  4.Children’s Hospital, Zhejiang University School of Medicine and National Clinical Research Center for Child Health, Hangzhou 310052, China
  5.Department of Hematology, Henan Provincial People’s Hospital, Zhengzhou 450003, China
  6.Department of Hematology, Tianjin First Central Hospital, Tianjin 300192, China
  7.Department of Hematology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China
  8.Department of Hematology, People’s Hospital of Zhengzhou, Zhengzhou 450003, China
  9.Department of Hematology, Sichuan Provincial People’s Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072, China
  10.Department of Hematology, Huai’an Second People’s Hospital, Huai’an 223002, Jiangsu, China
  11.Department of Hematology, the Third People’s Hospital of Zhengzhou, Zhengzhou 450003, China
  12.Department of Hematology, the Affiliated Tai’an City Central Hospital of Qingdao University, Tai’an 271000, Shandong, China
  13.Anhui Public Health Clinical Center, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
  14.The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
  15.Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha 410011, China
  16.Department of Hematology, Affiliated Hospital of Jining Medical University, Jining 272067, Shandong, China
  17.Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China
  18.Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China
- Author bio：
  
  * Xiao-Dong Mo moxiaodong@pkuph.edu.cn
- Funds：
- DOI：10.1186/s40779-025-00640-0
  CLC：
- Received：02 December 2024，
  
  Accepted：08 August 2025，
  
  Online First：29 September 2025，
  
  Published：2025
- Accepted：
Scan QR Code
Le-Qing Cao, Wen-Xuan Huo, Er-Lie Jiang, et al. Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study[J/OL]. Military Medical Research, 2025, 12.
DOI：

Le-Qing Cao, Wen-Xuan Huo, Er-Lie Jiang, et al. Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study[J/OL]. Military Medical Research, 2025, 12. DOI： 10.1186/s40779-025-00640-0.

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰

Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

DOI：10.1186/s40779-025-00640-0